Giovanna Bossi

This study shows that ImmTAAI, a beta cell-targeted PD-1 agonist, inhibits T cell activity in human type 1 diabetes by increasing T cell motility and reducing cytokine secretion.

The paper shows that T-cell activation is initiated by partial CD45 exclusion at sub-micron contacts, leading to strong activation and cytotoxicity through small signaling changes.